Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Instagram Outage Disrupts Thousands of U.S. Users 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
CHICAGO, March 31, 2016 -- The Female Health Company (NASDAQ:FHCO) (FHC or the Company) today announced the rollout of three large scale webinars by the FHC Education Team.
Developed to educate U.S. healthcare providers on reimbursability via the Affordable Care Act (ACA), the first webinar and accompanying materials were created with assistance from FHC’s partners the National Coalition of STD Directors (NCSD) and the National Family Planning and Reproductive Health Association (NFPRHA). These resources provide information and education to help women in the U.S. gain more affordable access to FC2 through ACA and/or Medicaid.
A separate webinar was held in partnership with The Southeast AIDS Education and Training Center (SEAETC) to provide FC2 refresher facts and updates. FHC also offered a comprehensive webinar update on FC2, with a focus on FC2 in the prevention of Zika, to the Regional Resource Network Program at the U.S. Department of Health and Human Services’ (HHS) ten regional offices.
On March 21, 2016, the first issue of the FHC U.S. Public Health Newsletter was distributed to more than 3,000 public health professionals. The newsletter will be issued bi-monthly and will alternate with a U.S. retail/commercial sector newsletter, launching in April 2016.
About The Female Health Company
The Female Health Company, based in Chicago, Illinois, manufactures and markets the FC2 Female Condom® (FC2). Since the Company began distributing FC2 in 2007, the product has been shipped to 144 countries. The Company owns certain worldwide rights to the FC2 Female Condom®, including patents that have been issued in a number of countries around the world. The patents cover key aspects of FC2, including its overall design and manufacturing process. The FC2 Female Condom® is the only currently available female-controlled product approved by FDA that offers dual protection against sexually transmitted infections, including HIV/AIDS, and unintended pregnancy. The World Health Organization (WHO) has cleared FC2 for purchase by U.N. agencies.
For more information about the Female Health Company visit the Company's website at http://www.femalehealth.com and http://www.femalecondom.org. If you would like to be added to the Company's e-mail alert list, please send an e-mail to [email protected].
Contacts: William R. Gargiulo, Jr. 231.526.1244 Michele Greco, CFO 312.595.9123
